Trenbolone; Estradiol; Tylosin Tartrate

Verify with FDA CVM →

85 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
85
Total Reports
53
Deaths Reported
6240.0%
Death Rate

Active Ingredients

Trenbolone; Estradiol; Tylosin Tartrate

Administration Routes

OtherUnknownSubcutaneousParenteralCutaneous

Species Affected

Cattle 76
Unknown 9

Most Affected Breeds

Cattle (unknown) 27
Crossbred Bovine/Cattle 26
Holstein-Friesian also known as Holstein 15
Unknown 9
Cattle (other) 2
Charolais 2
Mixed (Cattle) 2
Maine-Anjou 1
Holstein-Friesian - French Black Pied 1

Most Reported Reactions

Death 46
Behavioural disorder NOS 28
Unclassifiable adverse event 27
Respiratory tract disorder NOS 25
Digestive tract disorder NOS 17
Pneumonia 17
Lameness 16
Weight gain 9
Peritonitis 8
Ruminal bloat 8
Musculoskeletal disorder NOS 6
Reticulitis 6

Outcome Breakdown

Outcome Unknown
56 (44.4%)
Died
51 (40.5%)
Euthanized
8 (6.3%)
Ongoing
7 (5.6%)
Recovered/Normal
4 (3.2%)

Data Summary

Metric Value
Total adverse event reports 85
Reports involving death 53
Case-fatality rate (reported events) 6240.0%
Distinct species in reports 2
Distinct breeds in reports 9
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Trenbolone; Estradiol; Tylosin Tartrate Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 85 adverse event reports referencing Trenbolone; Estradiol; Tylosin Tartrate, including 53 reports in which the animal died — a 6240.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Trenbolone; Estradiol; Tylosin Tartrate. Reported administration routes include Other, Unknown, Subcutaneous, Parenteral. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Trenbolone; Estradiol; Tylosin Tartrate reports are Cattle (76 reports), Unknown (9 reports), with Cattle accounting for the largest share. Within those species, Cattle (unknown) (27), Crossbred Bovine/Cattle (26), Holstein-Friesian also known as Holstein (15) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Trenbolone; Estradiol; Tylosin Tartrate are Death (46), Behavioural disorder NOS (28), Unclassifiable adverse event (27), Respiratory tract disorder NOS (25). Of the 126 reports with a coded outcome, Outcome Unknown is the leading category at 44.4%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Trenbolone; Estradiol; Tylosin Tartrate.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial